Okabe, M <br/><br/>
BCR/ABL oncoprotein-targeted antitumor activity of antisense oligodeoxynucleotides complementary to bcr/abl mRNA and herbimycin A, an antagonist of protein tyrosine kinase: inhibitory effects on in vitro growth of Ph1-positive leukemia cells and BCR/ABL oncoprotein-associated transformed cells.  [electronic resource] 

 -  Leukemia & lymphoma  Jul 1993 
 - 307-16 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1042-8194 
<br/><br/><label>Standard No.: </label>10.3109/10428199309148553  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibiotics, Antineoplastic--pharmacology<br/>Base Sequence<br/>Benzoquinones<br/>Cell Division--drug effects<br/>DNA, Antisense--therapeutic use<br/>Dose-Response Relationship, Drug<br/>Fusion Proteins, bcr-abl--antagonists & inhibitors<br/>Humans<br/>Lactams, Macrocyclic<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Molecular Sequence Data<br/>Neoplasm Proteins--antagonists & inhibitors<br/>Philadelphia Chromosome<br/>Polymerase Chain Reaction<br/>Precursor Cell Lymphoblastic Leukemia-Lymphoma--drug therapy<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Quinones--pharmacology<br/>RNA-Directed DNA Polymerase<br/>Rifabutin--analogs & derivatives<br/>Tumor Cells, Cultured--drug effects